GSK drops $10 billion on a cancer drug company — speculate on the next biotech b
Thesis
Big pharmaceutical companies are facing expiration of patents on their current top-selling drugs, so they are forced to buy smaller biotech firms to replace those future revenues. GSK's massive $10.6 billion purchase of Nuvalent proves that major companies are willing to pay massive premiums for the right treatments. This signals that other small biotech companies with promising cancer or specialty drugs could soon be bought out too, making the whole sector highly attractive right now.
Strategy approach
Build a mean-reversion and relative-strength strategy on the daily timeframe. Scan for long entries on small and mid-cap biotech stocks (XBI constituents) when RSI(14) crosses above 50 and the stock closes above its 20-day EMA. Require the sector ETF (XBI) to be trending up (price > 50-day SMA). Use a 10% trailing stop and a 20-day max hold period.